The AI Impact Gap Is a MedComms Opportunity: What the 2025 Data Says

Posted in Uncategorized

88% of organisations now use AI. 32% see any sustained enterprise-wide value. The gap between those two numbers is the single biggest commercial opportunity inside medical communications for the next 18 months, and almost nobody is naming it.

The two numbers, from the primary sources

The 88% is from McKinsey’s [State of AI 2025](https://www.mckinsey.com/capabilities/quantumblack/our-insights/the-state-of-ai) (published November 2025, surveyed June to July 2025, accessed 22 April 2026). It describes adoption: AI is running somewhere inside 88% of organisations.

The 32% is from Accenture’s [Pulse of Change 2025](https://www.accenture.com/us-en/insights/pulse-of-change) (accessed 22 April 2026). It describes sustained, enterprise-wide AI impact: the kind a CFO can put in an annual report.

The 56-point gap between those numbers is not an implementation problem. It is a measurement problem. Organisations cannot prove the AI they deployed produced the value they were promised. Deloitte’s [State of AI in the Enterprise](https://www.deloitte.com/us/en/what-we-do/capabilities/applied-artificial-intelligence/content/state-of-ai-in-the-enterprise.html) (wave surveyed August to September 2025, accessed 22 April 2026) quantifies the problem from a different angle: only 34% of companies are truly reimagining their business around AI, while worker access to AI tools grew 50% in 2025. Tools everywhere. Redesigned workflow almost nowhere.

Why MedComms owns this gap

MedComms agencies sit between pharma / biotech clients and healthcare professionals. That position is exactly the right one to solve the AI impact gap for HCP education programmes, for three reasons.

One: the client is already asking. Pharma medical affairs teams spent the last ten years defending HCP education budgets on attendance and completion metrics. Those metrics are no longer enough. Procurement wants to know what changed. Regulators want to know what changed. Sales leadership wants to know whether the programme moved prescribing behaviour. “88% adoption” of AI does not answer any of those questions.

Two: the infrastructure to answer already exists, but it is a platform, not a slide deck. A persistent engagement layer that captures every HCP interaction across the programme year, tracks distance travelled from baseline to six-week follow-up, and produces a proof artefact automatically is the closest thing to an AI Chief of Staff that medical affairs has ever had. That is the redesigned workflow the Deloitte 34% are doing. MedComms agencies that adopt it first become the measurement-enabled agency in every pitch.

Three: the competitive window is narrow. Bain’s [Technology Report 2025](https://www.bain.com/insights/state-of-the-art-of-agentic-ai-transformation-technology-report-2025/) (accessed 22 April 2026) notes that AI leaders scaling their implementations deliver 10 to 25% EBITDA gains, while laggards do not. In agency terms: the agency that can show pharma procurement a distance-travelled proof report will win the retainer. The one still pitching a campaign plan will lose it. The window closes as measurement becomes table stakes, probably within 24 months.

The three traps to avoid

Not every response to the AI impact gap lands. Three common traps:

Trap 1: Bolt-on survey tools. A post-event survey is not measurement; it is self-reported completion. AI cannot turn a survey into behavioural evidence. The platform has to observe the HCP before, during, and six weeks after, that is Moore’s Level 5; otherwise the “AI measurement” claim collapses on the first client audit.

Trap 2: Single-campaign scope. A one-off programme cannot evidence distance travelled because it does not observe the HCP journey long enough. Recurring, year-round engagement is not a nice-to-have; it is the only architecture that produces defensible proof.

Trap 3: Feature-competing with pharma’s internal tools. Pharma medical affairs teams already have content, LMS systems, and data lakes. The MedComms agency’s job is not to replace those. It is to be the proof layer on top: the infrastructure that turns their existing content investment into client-facing evidence. Competing on features is a losing race. Competing on proof is an open field.

Where to start

Three low-friction first moves for a MedComms agency pursuing this opportunity:

1. Pick one existing programme. Retrofit a platform measurement layer on top of a live HCP education programme, even if only for a subset of HCPs. The goal is one Moore’s-Level-5 proof report in hand within 90 days.
   2. Quantify the current measurement stack. Work out what your clients can actually report to their own procurement teams today. The honest number is usually “activity metrics only”. That honesty is the hook for the upgrade conversation.
   3. Price the proof, not the platform. The commercial product is the proof artefact delivered quarterly, not the SaaS license. That reframes the conversation away from feature comparison and towards outcome delivery.

Yoke Health built HIVE specifically for this. It is the persistent measurement layer between events, the platform infrastructure the 34% of truly-redesigned enterprises have been putting in place, applied to HCP education.

The 56-point gap between AI adoption and AI impact is not going to close on its own. It closes when the measurement layer shows up.

Sources

: McKinsey. State of AI 2025. Published November 2025. [https://www.mckinsey.com/capabilities/quantumblack/our-insights/the-state-of-ai](https://www.mckinsey.com/capabilities/quantumblack/our-insights/the-state-of-ai) (accessed 22 April 2026)
. Deloitte. State of AI in the Enterprise (Aug to Sep 2025 wave). [https://www.deloitte.com/us/en/what-we-do/capabilities/applied-artificial-intelligence/content/state-of-ai-in-the-enterprise.html](https://www.deloitte.com/us/en/what-we-do/capabilities/applied-artificial-intelligence/content/state-of-ai-in-the-enterprise.html) (accessed 22 April 2026)
. Bain & Company. Technology Report 2025: State of the Art of Agentic AI Transformation. [https://www.bain.com/insights/state-of-the-art-of-agentic-ai-transformation-technology-report-2025/](https://www.bain.com/insights/state-of-the-art-of-agentic-ai-transformation-technology-report-2025/) (accessed 22 April 2026)
. Accenture. Pulse of Change 2025. [https://www.accenture.com/us-en/insights/pulse-of-change](https://www.accenture.com/us-en/insights/pulse-of-change) (accessed 22 April 2026)

### Legal notice
Sources cited in this post are the intellectual property of their respective publishers. Quoted statistics and findings are reproduced for editorial commentary and analysis under fair-dealing provisions of the UK Copyright, Designs and Patents Act 1988. Accessed dates are provided inline above. Readers are encouraged to consult the original source reports for full context and the full quantitative dataset. Yoke Health is not affiliated with, endorsed by, or sponsored by McKinsey & Company, Deloitte, Bain & Company, or Accenture.